Infection clinical trials at UC Irvine
1 research study open to eligible people
Showing trials for
Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS)
open to eligible people ages 18 years and up
BTI-203 is a randomized, double-blind, placebo-controlled, multicenter, Phase 2 proof-of-concept (POC) study to evaluate the efficacy and safety of rhu-pGSN plus standard of care (SOC) in subjects with moderate-to-severe ARDS (P/F ratio ≤150) due to pneumonia or other infections. Potential subjects hospitalized with pneumonia or other infections are to be screened within 24 hours of diagnosis of ARDS.
Irvine, California and other locations
Our lead scientists for Infection research studies include Alpesh Amin, MD.
Last updated: